Impact of clopidogrel and aspirin treatment on the expression of proteins in platelets from type-2 diabetic patients with stable coronary ischemia
| Autor: | José J. Zamorano-León, Antonio López Farré, Mateos-Cáceres Petra Jiménez, Segura Antonio, Macaya Carlos, Luis Azcona, Modrego Javier, Rodríguez Pablo |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Blood Platelets
Male Ticlopidine Proteome Molecular Sequence Data Pharmaceutical Science Coronary Disease Pharmacology Platelet Factor 4 chemistry.chemical_compound Lactate dehydrogenase medicine Humans Platelet cardiovascular diseases Platelet activation Amino Acid Sequence Aged Aspirin business.industry Coronary ischemia Clopidogrel medicine.disease Isotype Cytoskeletal Proteins chemistry Diabetes Mellitus Type 2 Gene Expression Regulation Drug Therapy Combination Female business Platelet factor 4 Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Journal of pharmaceutical sciences. 101(8) |
| ISSN: | 1520-6017 |
| Popis: | The purpose of this study was to compare the effect of dual antiplatelet therapy [clopidogrel + aspirin (ASA)] with respect to ASA on the protein expression of platelets from controlled type-2 diabetic patients with stable coronary ischemia. Patients had been taking ASA (100 mg day) and they were randomized to receive (n = 29) or not (n = 28) 75 mg day clopidogrel for 12 ± 2 weeks in a blind form. Protein expression was analyzed by two-dimensional electrophoresis and mass spectrometry. The protein expression of a limited number of proteins such as actin-binding protein isotypes 2 and 5, lactate dehydrogenase, serotransferrin isotype 4, protein disulfide isomerase-A3 isotype 1, fibrinogen beta chain isotype 5, Ras-related protein Rab-7b isotypes 1 and 6, and immunoglobulin heavy chain was changed after dual antiplatelet therapy. Plasma level of platelet factor 4 (PF4), an in vivo marker of platelet activity, was not different between both groups. These changes suggest lower platelet reactivity after dual antiplatelet therapy in the studied patients. However, the variation in platelet proteome was lower than it would be initially expected, taking into account the apparent clinical beneficial effects of dual antiplatelet therapy. PF4 plasma level was not further decreased in the platelets treated for a longer time than 9-12 months with ASA + clopidogrel, as compared with ASA alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text